Drug Topics

SEPTEMBER 13, 2024

Gilead said data from the study will support global regulatory filings that the company plans to begin by the end of the year.

PharmaVoice

SEPTEMBER 13, 2024

Three of the largest fundraising rounds in 2024 show where investors are willing to place their bets in biotech.

Drug Topics

SEPTEMBER 13, 2024

During an interview, Joseph Shields of TransparencyRx discusses the PBM legislation that is expected to move forward in Congress in the next few months.

Pharmacy Times

SEPTEMBER 13, 2024

AI is significantly enhancing the efficiency of identifying and enrolling patients.

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patient Care

Drug Topics

SEPTEMBER 13, 2024

Researchers conducted a meta-analysis detailing previous patient outcomes in response to visual art therapy interventions.

Pharmacy Times

SEPTEMBER 13, 2024

In the absence of a common treatment for long COVID, researchers from around the world documented the best currently available therapies.

Documentation

Pharmacy Is Right For Me

SEPTEMBER 13, 2024

Written by: Toni Mikhael, PharmD, Touro College of Pharmacy Class of 2024. PGY-1 Pharmacy Resident, WellSpan Ephrata Community Hospital, Ephrata, PA Edited by: Anastasiya Shor, PharmD, BCPS Pharmacy school is a challenging but rewarding journey. As students embark on this demanding path, it becomes crucial to equip themselves with a toolkit for success.

Medical Schools

Drug Topics

SEPTEMBER 13, 2024

Over 30 million American adults experience some hearing loss, yet only one-fifth benefit from hearing aids; the FDA’s approval will expand access to the technology for the patient population.

FDA

STAT

SEPTEMBER 13, 2024

A close contact of the person in Missouri who had an unexplained H5N1 bird flu infection last month was also sick around the same time, but was not tested for influenza, the Centers for Disease Control and Prevention reported on Friday.  The CDC revealed the previously undisclosed information in FluView , its weekly report on influenza activity.

Drug Topics

SEPTEMBER 13, 2024

Check out important updates from the FDA for the week of August 9.

FDA

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

STAT

SEPTEMBER 13, 2024

For more cancer coverage, sign up for STAT’s pop-up newsletter focused on this weekend’s European Society for Medical Oncology conference, one of the biggest oncology meetings of the year. Details here. When Rachel Guberman found out she had brain cancer, she did so much reading and Googling about the disease that she joked she had reached the end of the internet.

Chemotherapy

Pharmaceutical Technology

SEPTEMBER 13, 2024

Distribution of the self-amplifying mRNA vaccine Kostaive is set to align with a planned October 2024 Covid-19 vaccination campaign.

Vaccines

STAT

SEPTEMBER 13, 2024

For years, health insurers battled to gain market share in the lucrative privatized Medicare program. Now, the opposite is true. Some of the companies say they designed their 2025 plans with an eye toward ditching members.  Health insurance has always been cyclical — companies go all-in on certain business lines when they’re profitable and get out when they’re not — but next year will mark a particularly drastic turning point for Medicare Advantage , the form of

Insurance

Pharmacy Times

SEPTEMBER 13, 2024

Data show the value of the pharmacist is clear for patients with type 2 diabetes, as their role can have a significant impact on reductions in hemoglobin A1c.

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

STAT

SEPTEMBER 13, 2024

BARCELONA, Spain — A targeted immunotherapy being developed by the biotech iTeos Therapeutics and GSK delivered promising response rates in patients with a type of lung cancer, propelling the treatment into a pivotal Phase 3 trial and adding fuel to a broader debate about the validity of the target. The companies reported on Saturday that their combination of a TIGIT-targeting antibody and GSK’s Jemperli increased the percentage of patients who saw their tumors shrink versus those

Pharmacy Times

SEPTEMBER 13, 2024

The Hearing Aid Feature can be customized to the user’s needs by amplifying sounds for individuals 18 years or older who have perceived mild to moderate hearing impairments.

FDA

STAT

SEPTEMBER 13, 2024

I first met Jane (not her real name, of course) on a Friday afternoon in our clinic. She was referred for further evaluation of her chest pain, which, in the context of her family history of early-onset heart attacks and her morbid obesity, understandably concerned her primary care doctor. In the exam room, we dissected her symptoms and decided we’d investigate them further with a stress test.

Compounding

Pharmacy Times

SEPTEMBER 13, 2024

These results build off the PURPOSE 1 trial, contributing to the wealth of evidence surrounding lenacapavir’s positive effects in patients with HIV.

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

Fierce Healthcare

SEPTEMBER 13, 2024

UTHealth Houston unveiled a partnership with OpenAI on Friday to build and deploy algorithms for use in medical training and at the patient’s bedside. | UTHealth Houston, an academic medical center in Texas, is partnering with OpenAI to give clinicians, faculty and students access to ChatGPT tools to build custom, HIPAA-compliant AI solutions.

HIPAA

STAT

SEPTEMBER 13, 2024

Swiss pharma giant Roche won approval from the Food and Drug Administration on Friday for an injectable version of its blockbuster multiple sclerosis therapy Ocrevus, cutting down the time needed to treat patients and potentially staving off growing competition. The approval was driven by the results of a late-stage trial , OCARINA II, in which the company showed that delivering Ocrevus as a 10-minute injection beneath the skin worked as well as the current approach, an hours-long intravenous in

FDA

Pharmacy Times

SEPTEMBER 13, 2024

The approval marks the first and only twice yearly, health care professional-administrated injection for both forms of multiple sclerosis (MS).

FDA

Fierce Healthcare

SEPTEMBER 13, 2024

Employers are bracing for a third straight year with health benefit costs increasing more than 5%, according to a new report from Mercer. | Employers are bracing for a third straight year with health benefit cost increases of more than 5%, according to a new report from Mercer.

Pharmacy Times

SEPTEMBER 13, 2024

Exposure to high cholesterol levels is a significant risk factor for atherosclerosis cardiovascular disease.

STAT

SEPTEMBER 13, 2024

BARCELONA, Spain — Adding a second immunotherapy from Bristol Myers Squibb to an existing checkpoint inhibitor and chemotherapy improved responses for certain patients with a type of lung cancer, steering the approach into a Phase 3 study.  The Phase 2 RELATIVITY-104 trial was another hurdle for BMS’ Opdualag, which is essentially a combination of the company’s powerhouse PD-1 inhibitor Opdivo and relatlimab, which targets another checkpoint called LAG-3.

Chemotherapy

Pharmacy Times

SEPTEMBER 13, 2024

Researchers suggest prior treatments and follow-up duration may play a larger role.

Fierce Pharma

SEPTEMBER 13, 2024

It’s better late than never for an FDA approval for the first subcutaneous PD-L1 inhibitor, which was doled out to Roche’s Tecentriq Hybreza after manufacturing delays derailed the company's initia | The under-the-skin formulation trims administration time down to seven minutes compared to the 30 to 60 minutes needed for intravenous Tecentriq.

FDA

STAT

SEPTEMBER 13, 2024

Want to stay on top of the science and politics driving biotech today?  Sign up  to get our biotech newsletter in your inbox. Good morning, and congratulations on making it through another week. What’s been helping me get through this week is this baby hippo in Thailand called Moo Deng (which apparently translates to Bouncy Pig). She is very likely the cutest and most relatable animal I’ve ever seen.

Pharmacy Times

SEPTEMBER 13, 2024

As access becomes easier, pharmacists are more likely to encounter questions.

Patient Care

STAT

SEPTEMBER 13, 2024

This is the online edition of ESMO in 30 Seconds, a pop-up newsletter from the European Society for Medical Oncology’s annual meeting in Barcelona, Spain. Sign up for the remaining editions here. One of the big presentations of this year’s ESMO (at least in our view) comes tomorrow morning bright and early. David Spigel of Sarah Cannon Research Institute in Nashville will unveil results from the GALAXIES Lung-201 study of an anti-TIGIT therapy from iTeos Therapeutics and GSK in non

Fierce Pharma

SEPTEMBER 13, 2024

When Roche's Genentech gained approval for Ocrevus in 2017, the first-in- | The day after Roche gained an FDA approval for its subcutaneous version of cancer drug Tecentriq, the company also scored with a U.S. nod for its under-the-skin formulation of mega-blockbuster multiple sclerosis drug Ocrevus. The approval gives patients a more convenient injected way to receive Ocrevus as opposed to the infused formulation.

FDA

pharmaphorum

SEPTEMBER 13, 2024

AI-driven solutions are revolutionising the pharmaceutical supply chain management process, particularly in reducing drug shortages. Learn more about the power of AI in this field.

Fierce Pharma

SEPTEMBER 13, 2024

Daiichi Sankyo and AstraZeneca are padding the case for their antibody-drug conjugate Enhertu with new data demonstrating the medicine’s worth in patients whose cancer has spread to the b | To bolster Enhertu's case in HER2-positive breast cancer, AstraZeneca and Daiichi Sankyo have rolled out positive data for the antibody-drug conjugate in patients who have brain metastases.

Fierce Healthcare

SEPTEMBER 13, 2024

Lawmakers scrutinize sluggish efforts to overhaul organ transplants as HHS aims to expand access for HIV-positive patients dmuoio Fri, 09/13/2024 - 17:08